Background: Hyperkalemia is a common medical emergency that may result in serious cardiac arrhythmias. Standard therapy with insulin plus glucose reliably lowers the serum potassium concentration ([K+]) but carries the risk of hypoglycemia. This study examined whether an intravenous glucose-only bolus lowers serum [K+] in stable, nondiabetic, hyperkalemic patients and compared this intervention with insulin-plus-glucose therapy. Methods: A randomized, crossover study was conducted in 10 chronic hemodialysis patients who were prone to hyperkalemia. Administration of 10 units of insulin with 100 ml of 50% glucose (50 g) was compared with the administration of 100 ml of 50% glucose only. Serum [K+] was measured up to 60 min. Patients were monitored for hypoglycemia and EKG changes. Results: Baseline serum [K+] was 6.01 ± 0.87 and 6.23 ± 1.20 mmol/l in the insulin and glucose-only groups, respectively (p = 0.45). At 60 min, the glucose-only group had a fall in [K+] of 0.50 ± 0.31 mmol/l (p < 0.001). In the insulin group, there was a fall of 0.83 ± 0.53 mmol/l at 60 min (p < 0.001) and a lower serum [K+] at that time compared to the glucose-only group (5.18 ± 0.76 vs. 5.73 ± 1.12 mmol/l, respectively; p = 0.01). In the glucose-only group, the glucose area under the curve (AUC) was greater and the insulin AUC was smaller. Two patients in the insulin group developed hypoglycemia. Conclusion: Infusion of a glucose-only bolus caused a clinically significant decrease in serum [K+] without any episodes of hypoglycemia.

Keywords:
Clinical trial, Glucose, Hyperkalemia, Hypoglycemia, Insulin
1.
Acker CG, Johnson JP, Palevsky PM, Greenberg A: Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998;158:917-924.
2.
Stevens MS, Dunlay RW: Hyperkalemia in hospitalized patients. Int Urol Nephrol 2000;32:177-180.
3.
Kamel KS, Wei C: Controversial issues in the treatment of hyperkalaemia. Nephrol Dial Transplant 2003;18:2215-2218.
4.
Schwarz KC, Cohen BD, Lubash GD, Rubin AL: Severe acidosis and hyperpotassemia treated with sodium bicarbonate infusion. Circulation 1959;19:215-220.
5.
Danowski TS, Greenman L, Mateer FM, Parsons WB, Weigand FA, Mermelstein H, Peters JH: Carboxylic cation exchange resin effects in dogs. J Clin Invest 1951;30:984-994.
6.
Gruy-Kapral C, Emmett M, Santa Ana CA, Porter JL, Fordtran JS, Fine KD: Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol 1998;9:1924-1930.
7.
Lillemoe KD, Romolo JL, Hamilton SR, Pennington LR, Burdick JF, Williams GM: Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery 1987;101:267-272.
8.
Gerstman BB, Kirkman P, Platt R: Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am J Kidney Dis 1992;20:159-161.
9.
McGowan CE, Saha S, Chu G, Resnick MB, Moss SF: Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J 2009;102:493-497.
10.
Sterns RH, Rojas M, Bernstein P, Chennupati S: Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010;21:733-735.
11.
Kamel KS, Schreiber M: Asking the question again: are cation exchange resins effective for the treatment of hyperkalemia? Nephrol Dial Transplant 2012;27:4294-4297.
12.
Rosić N, Standaert M, Pollet R: The mechanism of insulin stimulation of (Na+, K+)-ATPase transport activity in muscle. J Biol Chem 1985;260:6206-6212.
13.
Blumberg A, Weidmann P, Shaw S, Gnädinger M: Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med 1988;85:507-512.
14.
Lens XM, Montoliu J, Cases A, Campistol JM, Revert L: Treatment of hyperkalemia in renal failure: salbutamol v. insulin. Nephrol Dial Transplant 1989;4:228-232.
15.
Allon M, Copkney C: Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 1990;38:869-872.
16.
Mahajan S, Mangla M, Kishore K: Comparison of aminophylline and insulin-dextrose infusions in acute therapy of hyperkalemia in end-stage renal disease patients. J Assoc Physicians India 2001;49:1082-1085.
17.
Williams PS, Davenport A, Bone JM: Hypoglycaemia following treatment of hyperkalaemia with insulin and dextrose. Postgrad Med J 1988;64:30-32.
18.
Schafers S, Naunheim R, Vijayan A, Tobin G: Incidence of hypoglycemia following insulin-based acute stabilization of hyperkalemia treatment. J Hosp Med 2012;7:239-242.
19.
Tarail R, Seldin DW, Goodyear AV: Effects of injection of hypertonic glucose on metabolism of water and electrolytes in patients with edema. J Clin Invest 1951;30:1111-1119.
20.
Groen J, Willebrands AF, Kamminga CE, Van Schothorst HK, Godfried EG: Effects of glucose administration on the potassium and inorganic phosphate content of the blood serum and the electrocardiogram in normal individuals and in non-diabetic patients. Acta Med Scand 1952;141:352-366.
21.
Marks PA, Bishop JS: The glucose metabolism of patients with malignant disease and of normal subjects as studied by means of an intravenous glucose tolerance test. J Clin Invest 1957;36:254-264.
22.
Muto S, Sebata K, Watanabe H, Shoji F, Yamamoto Y, Ohashi M, Yamada T, Matsumoto H, Mukouyama T, Yonekura T, Namiki S, Kusano E: Effect of oral glucose administration on serum potassium concentration in hemodialysis patients. Am J Kidney Dis 2005;46:697-705.
23.
Evans KJ, Greenberg A: Hyperkalemia: a review. J Intensive Care Med 2005;20:272-290.
24.
Weisberg LS: Management of severe hyperkalemia. Crit Care Med 2008;36:3246-3251.
25.
DeFronzo RA, Andres R, Edgar P, Walker WG: Carbohydrate metabolism in uremia: a review. Medicine (Baltimore) 1973;52:469-481.
26.
Porte DJ: Sympathetic regulation of insulin secretion. Arch Intern Med 1969;123:252-260.
27.
Goldfarb S, Cox M, Singer I, Goldberg M: Acute hyperkalemia induced by hyperglycemia: hormonal mechanisms. Ann Intern Med 1976;84:426-432.
28.
Ammon RA, May WS, Nightingale SD: Glucose-induced hyperkalemia with normal aldosterone levels. Studies in a patient with diabetes mellitus. Ann Intern Med 1978;89:349-351.
29.
Conte G, Dal Canton A, Imperatore P, De Nicola L, Gigliotti G, Pisanti N, Memoli B, Fuiano G, Esposito C, Andreucci VE: Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int 1990;38:301-307.
30.
DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J: Insulin resistance in uremia. J Clin Invest 1981;67:563-568.
31.
Mak RH, DeFronzo RA: Glucose and insulin metabolism in uremia. Nephron 1992;61:377-382.
32.
Alvestrand A: Carbohydrate and insulin metabolism in renal failure. Kidney Int 1997;62:S48-S52.
33.
Alvestrand A, Wahren J, Smith D, DeFronzo RA: Insulin-mediated potassium uptake is normal in uremic and healthy subjects. Am J Physiol 1984;246:E174-E180.
34.
Cheema-Dhadli S, Chong C-K, Kamel KS, Halperin ML: An acute infusion of lactic acid lowers the concentration of potassium in arterial plasma by inducing a shift of potassium into cells of the liver in fed rats. Nephron Physiol 2012;120:7-15.
35.
Juel C, Halestrap AP: Lactate transport in skeletal muscle - role and regulation of the monocarboxylate transporter. J Physiol 1999;517:633-642.
36.
Counillon LL, Pouyssegur RJ: The members of the Na+/H+ exchanger gene family: their structure, function, expression, and regulation; in Seldin DW, Giebisch G (eds): The Kidney: Physiology and Pathophysiology. Philadelphia, Lippincott Williams & Wilkins, 2000, vol 1, pp 223-234.
37.
Tsujimoto T, Yamamoto-Honda R, Kajio H, Kishimoto M, Noto H, Hachiya R, Kimura A, Kakei M, Noda M: Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients. Diabetes Care 2014;37:217-225.
38.
Ljutic D, Rumboldt Z: Should glucose be administered before, with, or after insulin, in the management of hyperkalemia? Ren Fail 1993;15:73-76.
39.
Allon M, Shanklin N: Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Am J Kidney Dis 1996;28:508-514.
40.
Kim HJ: Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. Nephron 1996;72:476-482.
41.
Ngugi N, McLigeyo S, Kayima J: Treatment of hyperkalaemia by altering the transcellular gradient in patients with renal failure: effect of various therapeutic approaches. East Afr Med J 1997;74:503.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.